In Brief: Consummated Productivity
This article was originally published in The Tan Sheet
Executive Summary
Consummated Productivity: Firm receives Dec. 9 FDA warning letter stating that marketing materials for the Edison, N.J.-based company's Bio Normalizer ginseng capsules make unapproved new drug claims implying the product treats "fatal viral infection and advanced cancer" and "prevents spread and metastasis of illness." The product is misbranded, the agency declares, in that it bears inadequate directions and the unsubstantiated suggestion that ginseng capsules are safe and effective for the labeled uses. FDA notes it also has reviewed a testimonial letter and promotional brochures including claims such as "insulin dependent diabetes (type 1) and in children with chronic virus hepatitis B and hepatitis C," "chronic respiratory failure due to pulmonary tuberculosis" and "abstinence-induced oxidative stress in alcoholics is improved by Bio Normalizer"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning